Overcoming Barriers to Pain Relief: An Interactive Patient Case Symposium CME

Lesley M. Arnold, MD; Scott M. Fishman, MD; Lee S. Simon, MD Author Information and Disclosures

Release Date: February 4, 2008; Valid for credit through February 4, 2009

Credits Available
Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™ for physicians

The content of this CME activity, "Overcoming Barriers to Pain Relief: An Interactive Patient Case Symposium", was developed by the faculty.

To participate in this activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Health Education Alliance, Inc.
Pfizer
Learning Objectives

Upon completion of this activity, participants should be able to:

  1. Reinforce the clinical management goals for clinicians who care for patients with osteoarthritis and rheumatoid arthritis and compare and contrast the nonpharmacologic, pharmacologic, and surgical interventions for patients with arthritis.
  2. Describe the public health, work-related, and personal costs associated with chronic back pain and discuss the pharmacologic and nonpharmacologic interventions that are used to treat this pain syndrome.
  3. Outline the prevalence, risk factors, and pathogenesis of fibromyalgia and devise a treatment plan that comprises evidence-based pharmacologic and nonpharmacologic interventions.
  4. Review the mechanisms underlying the development of neuropathic pain and describe prevention and treatment strategies for commonly encountered types of neuropathic pain.
Author Disclosures and Policy
Policy On Faculty And Provider Disclosure

It is the policy of Beth Israel Medical Center & St. Luke's and Roosevelt Hospitals that faculty and providers disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Beth Israel Medical Center & St. Luke's and Roosevelt Hospitals have established policies in place that will identify and resolve all conflicts of interest prior to this educational activity.


Lesley M. Arnold, MD
Disclosure: Grant/Research Support: Allergan, Boehringer Ingelheim, Cypress Biosciences, Inc., Eli Lilly and Company, Forest Laboratories, Pfizer Inc, sanofi-aventis, Wyeth Pharmaceuticals; Consultant: Allergan, Boehringer Ingelheim, Cypress Biosciences, Inc., Eli Lilly and Company, Forest Laboratories, Pfizer Inc, sanofi-aventis, Sepracor, Vivus, Inc, Wyeth Pharmaceuticals; Speakers' Bureau: Eli Lilly and Company, Pfizer Inc


Scott M. Fishman, MD
Disclosure: Grant/Research Support, Consultant, Speakers' Bureau: Elan Co., Endo Pharmaceuticals, Janssen Medical Affairs, LLC, Merck & Co., Inc., Pfizer Inc, Purdue Pharma, L.P.; Consultant: Cephalon, Inc., Eli Lilly and Company


Lee S. Simon, MD
Disclosure: Consultant: AAI Pharma, Abbott Laboratories, Abraxxis, Affinergy, Alder, Alimera, Alpha Rx, Altea, AstraZeneca, Avanir, Bayer, Biosense, Cellegy, Cell Therapeutics, Cerimon, Chelsea, Chemocentryx, Coley, Combinatoryx, Cure, Cypress, Diobex, Dr. Reddy's, Gynelabs, Hisamatsu, Jazz, LAB Pharma, Leerink Swann, Luxor, McKesson, Medimmune, Millennium Pharmaceuticals, Neopharm, Neuromed, Nitec, Nomura, Novartis, Nuvo/Dimethaid, Omeros, Paraexel, Pfizer Inc, PLx Pharma, Polymerix, Procter and Gamble, Proethic, Proprius, Purdue Pharma, Puretech Development, Puretechventures, Regeneron, Rigel, Savient, Schwarz, Skyepharma, Sepracor, Serono, SNBL, Solace, TAP, Takeda, Talagen, Teva, Tigenix, White Mountain Pharma, Zydus
 
Beth Israel
Health Education Alliance

Joint Sponsorship



Accreditation Statements
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Beth Israel Medical Center & St. Luke's and Roosevelt Hospitals and Health Education Alliance, Inc. Beth Israel Medical Center & St. Luke's and Roosevelt Hospitals are accredited by the ACCME to provide continuing medical education for physicians.


Credit Designation
Beth Israel Medical Center designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.